Plinabulin

Drug Profile

Plinabulin

Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; National Cancer Institute (USA); Nereus Pharmaceuticals; University of Washington
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Guanine nucleotide exchange factor stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II/III Neutropenia
  • Preclinical Glioblastoma
  • Research Brain cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 26 Oct 2017 Phase-II/III clinical trials in Neutropenia (Prevention, Chemotherapy-induced, Combination therapy) in USA and China (IV) (NCT03294577)
  • 25 Oct 2017 Phase-II/III clinical trials in Neutropenia (Prevention, Chemotherapy-induced) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top